BioSpace News Archive

T2 Biosystems, Inc. (NASDAQ:TTOO), leader in the rapid detection of sepsis-causing pathogens and antibiotic resistance genes, announced today that it will report financial results for the first quarter 2023 after market close on Monday, May 15, 2023.

Celularity Inc. announced that Adrian Kilcoyne, M.D., M.P.H., M.B.A., Celularity’s Chief Medical Officer, will present data at the upcoming 26th Annual Meeting of the American Society of Gene & Cell Therapy, which will be held May 16-20th in Los Angeles.

Femasys Inc. (NASDAQ: FEMY) today announced that the Company’s management team will be attending the annual Conference for the American Society for Colposcopy and Cervical Pathology (ASCCP) held May 4 -7, 2023 at the Marriott Marquis in Houston.

OrthoPediatrics Corp., a company focused exclusively on advancing the field of pediatric orthopedics, announced its financial results for the first quarter ended March 31, 2023.

Reviva Pharmaceuticals Holdings, Inc. (NASDAQ: RVPH) (“Reviva” or the “Company”) has presented the foundational preclinical data that supported the initial clinical development of its novel serotonin-dopamine stabilizer brilaroxazine at the 78th Annual Scientific Convention of the Society of Biological Psychiatry (SOBP) in San Diego.

Sight Sciences, Inc. announced that two of its proprietary glaucoma and dry eye technologies, the OMNI® Surgical System and the TearCare® System, will be featured in oral presentations and one poster at this year’s ASCRS Annual meeting at the San Diego Convention Center in San Diego, CA.

Travere Therapeutics, Inc. (Nasdaq: TVTX) today announced topline primary efficacy results from the pivotal Phase 3 DUPLEX Study of sparsentan, a Dual Endothelin Angiotensin Receptor Antagonist (DEARA), in focal segmental glomerulosclerosis (FSGS).

Florida Cancer Specialists & Research Institute, LLC is pleased to welcome two Board-certified medical oncologists to its Delray clinic in Palm Beach County.

Palatin Technologies, Inc., a biopharmaceutical company developing first-in-class medicines based on molecules that modulate the activity of the melanocortin receptor system, announced it will host a key opinion leader webinar on May 8, 2023 at 11:00 a.m. ET.

Calyxt, Inc. (Nasdaq: CLXT), a plant-based synthetic biology company, today announced operating and financial results for its first quarter ended March 31, 2023.